Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

STOP-MSU: Stopping Haemorrhage With Tranexamic Acid for Hyperacute Onset Presentation Including Mobile Stroke Units

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03385928
Recruitment Status : Recruiting
First Posted : December 29, 2017
Last Update Posted : December 5, 2019
Sponsor:
Collaborator:
The Florey Institute of Neuroscience and Mental Health
Information provided by (Responsible Party):
Neuroscience Trials Australia

Brief Summary:

The study will be prospective phase II randomised, double-blind, placebo-controlled, investigator-driven trial in acute intracerebral haemorrhage patients.

The study has 2 arms with 1:1 randomisation to either intravenous Tranexamic acid or placebo and will test the hypothesis that ICH (intracranial haemorrhage) patients treated with intravenous tranexamic acid within 2 hours of symptom onset will have lower rates of haematoma growth than compared to placebo.


Condition or disease Intervention/treatment Phase
Intracerebral Haemorrhage Drug: Tranexamic Acid Drug: Normal saline Phase 2

Detailed Description:
The trial will include patients with acute spontaneous ICH, who are ≥18 years of age and are eligible for treatment within 2 hours of stroke onset. A sample size of 62 patients is calculated to give 80% power to detect a large effect size assuming mean relative ICH haematoma growth of 38% in the placebo arm compared to 19% in the active treatment arm and standard deviation of 19%, inflated for nonparametric analysis. Adaptive increase in sample size will be performed if the result of interim analysis of the first 50 patients is promising, using the methodology of Mehta and Pocock.1 The maximum sample size is capped at 124. Standard CT for initial diagnosis of suspected stroke patients will be performed. Neurological impairment and functional scores will be measured by a neurologist or health care professional trained in their administration. The assessors will be blinded to the treatment group. Patients eligible for the RCT will be randomised in a 1:1 ratio to receive either Tranexamic acid or placebo stratified by treating centre and utilising randomly permuted blocks of random size.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 62 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

The study will be prospective phase II randomised, double-blind, placebo-controlled investigator-driven trial in acute intracerebral haemorrhage patients.

The study has 2 arms with 1:1 randomisation to either intravenous Tranexamic acid or placebo.

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: STOP-MSU: Stopping Haemorrhage With Tranexamic Acid for Hyperacute Onset Presentation Including Mobile Stroke Units. A Phase II Randomised, Placebo-controlled, Investigator-driven Trial of Tranexamic Acid Within 2 Hours of Intracerebral Haemorrhage
Actual Study Start Date : March 19, 2018
Estimated Primary Completion Date : December 1, 2020
Estimated Study Completion Date : March 1, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bleeding

Arm Intervention/treatment
Active Comparator: Tranexamic acid
Intravenous tranexamic acid 1000 mg in 100 mL 0.9% NaCl over 10 minutes followed by 1000 mg in 500 mL 0.9% NaCl infusion over 8 hours.
Drug: Tranexamic Acid
Investigational product given within 2 hours of symptom onset

Placebo Comparator: Normal Saline (0.9% NaCl)
100 mls intravenous 0.9%NaCl over 10 minutes followed by 500 ml intravenous 0.9% NaCl infusion over 8 hours.
Drug: Normal saline
Placebo given within 2 hours of symptom onset
Other Name: 0.9%NaCl




Primary Outcome Measures :
  1. Relative ICH haematoma growth at 24±3 hours, adjusted for baseline ICH volume (mls) [ Time Frame: 24 hours(plus or minus 3 hours) ]
    Relative ICH haematoma growth


Secondary Outcome Measures :
  1. ICH growth [ Time Frame: 24 hours (plus or minus 3 hours) ]
    ICH growth as defined by either 33% or 6ml increase from baseline, adjusted for baseline ICH volume

  2. Absolute ICH growth (mls) [ Time Frame: 24 hours (plus or minus 3 hours) ]
    Absolute ICH growth

  3. Relative ICH growth volume (mls) [ Time Frame: 1 hour after baseline CT ]
    Relative and absolute ICH growth volume, adjusted for baseline ICH volume

  4. Major thromboembolic events [ Time Frame: 3 months ]
    Major thromboembolic events (myocardial infarction, ischaemic stroke, pulmonary embolism) or death

  5. Intraventricular haematoma growth [ Time Frame: 24 hours (plus or minus 3 hours) ]
    Absolute intraventricular haematoma (IVH) growth volume adjusted for baseline IVH volume

  6. Modified Rankin Scale (mRS) [ Time Frame: 3 months ]
    mRS 0-4 or back to pre-stroke level, or mRS 0-3 or back to pre-stroke level (with lowest mRS score being the better outcome)

  7. Modified Rankin Scale (mRS) [ Time Frame: 3 months ]
    Categorical shift in mRS (0-6 with 6 being worst outcome)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients presenting with an acute ICH
  2. Age ≥18 years
  3. Treatment can commence within 2 hours of symptom onset (or in patients with unknown time of symptom onset, the time patient was last known to be well)
  4. Consent can be obtained from participant or person responsible. When emergency treatment procedures have been followed the participant or person responsible will be asked for consent to continue in the study.

Exclusion Criteria:

  1. Glasgow coma scale (GCS) total score of <8
  2. Brainstem ICH
  3. ICH volume >70 ml as measured by the ABC/2 method
  4. ICH known or suspected by study investigator to be secondary to trauma, aneurysm, vascular malformation, haemorrhagic transformation of ischaemic stroke, cerebral venous thrombosis, thrombolytic therapy, tumour, or infection
  5. Any history or current evidence suggestive of venous or arterial thrombotic events within the previous 12 months, including clinical, ECG, laboratory, or imaging findings. Clinically silent chance findings of old ischemia are not considered exclusion.
  6. Hereditary or acquired haemorrhagic diathesis or coagulation factor deficiency.
  7. Use of heparin, low-molecular weight heparin, GPIIb/IIIa antagonist, or oral anticoagulation (e.g. warfarin, factor Xa inhibitor, thrombin inhibitor) within the previous 14 days, irrespective of laboratory values
  8. Pregnancy (women of childbearing potential must be tested)
  9. Planned surgery for ICH within 24 hours
  10. Concurrent or planned treatment with haemostatic agents (e.g. prothrombin complex concentrate, vitamin K, fresh frozen plasma, or platelet transfusion)
  11. Participation in any investigational study in the last 30 days
  12. Known terminal illness or planned withdrawal of care or comfort care measures
  13. Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03385928


Contacts
Layout table for location contacts
Contact: Henry Zhao, MD +61 3 9342 7000 henry.zhao@mh.org.au
Contact: Michele Sallaberger 0438 471 423 michele.sallaberger@florey.edu.au

Locations
Layout table for location information
Australia, New South Wales
Liverpool Hospital Recruiting
Liverpool, New South Wales, Australia, 2170
Contact: Cheryl Qi Cheng    +61 2 8738 7170    Qi.Cheng@health.nsw.gov.au   
Principal Investigator: Andrew Cheung         
Australia, Queensland
Sunshine Coast University Hospital Recruiting
Birtinya, Queensland, Australia, 4575
Contact: Karen Simmons    +61 7 5202 3155    Karen.Simmons@health.qld.gov.au   
Principal Investigator: Rohan Grimley         
Princess Alexandra Hospital Recruiting
Woolloongabba, Queensland, Australia, 4102
Contact: Carol Bendall    +61 7 3176 5169    SRUPAH@health.qld.gov.au   
Principal Investigator: Darshan Shah         
Australia, South Australia
Royal Adelaide Hospital Recruiting
Adelaide, South Australia, Australia, 5000
Contact: Roy Drew       Roy.Drew@sa.gov.au   
Principal Investigator: Timothy Kleinig         
Australia, Victoria
Box Hill Hospital Recruiting
Box Hill, Victoria, Australia, 3128
Contact: Grace Thomas    +61 3 9094 9541    Grace.Thomas@monash.edu   
Principal Investigator: Philip Choi         
Monash Medical Centre Recruiting
Clayton, Victoria, Australia, 3168
Contact: Veronic Hervet       Marie.Hervet@monashhealth.org   
Principal Investigator: Henry Ma         
Alfred Hospital Recruiting
Melbourne, Victoria, Australia, 3004
Contact: Andrea Moore    +61 3 9076 3581    andrea.moore@alfred.org.au   
Principal Investigator: Geoffrey Cloud         
Royal Melbourne Hospital Recruiting
Melbourne, Victoria, Australia
Contact: Stephen Davis         
Principal Investigator: Stephen Davis         
New Zealand
CDHB Christchurch Hospital Recruiting
Christchurch, New Zealand, 8140
Contact: Jane Eagle    +64 3 378 6130    Jane.Eagle@cdhb.health.nz   
Principal Investigator: Teddy Wu         
Wellington Hospital Recruiting
Wellington, New Zealand, 6021
Contact: Brianne Boljonis       Brianne.Boljonis@ccdhb.org.nz   
Principal Investigator: Anna Ranta         
Sponsors and Collaborators
Neuroscience Trials Australia
The Florey Institute of Neuroscience and Mental Health
Investigators
Layout table for investigator information
Principal Investigator: Geoffrey Donnan, MD The Florey Institute of Neuroscience and Mental Health
Principal Investigator: Stephen Davis, MD Melbourne Health Dept of Neurology & The University of Melbourne Dept of Medicine
Principal Investigator: Henry Zhao, MD Melbourne Health Dept of Neurology & The University of Melbourne Dept of Medicine
Layout table for additonal information
Responsible Party: Neuroscience Trials Australia
ClinicalTrials.gov Identifier: NCT03385928    
Other Study ID Numbers: NTA1702
First Posted: December 29, 2017    Key Record Dates
Last Update Posted: December 5, 2019
Last Verified: December 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Neuroscience Trials Australia:
ICH
Stroke
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Tranexamic Acid
Antifibrinolytic Agents
Fibrin Modulating Agents
Pharmacologic Actions
Cardiovascular Agents
Therapeutic Uses
Hematologic Agents
Hemostatics
Contrast Media
Angiography
Cerebral Angiography
Tomography, X-Ray Computed
Additional relevant MeSH terms:
Layout table for MeSH terms
Cerebral Hemorrhage
Hemorrhage
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Pathologic Processes
Intracranial Hemorrhages
Tranexamic Acid
Antifibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Hemostatics
Coagulants